1887

Abstract

Tick-borne encephalitis virus (TBEV) encodes a conserved, immunogenic, non-structural protein NS1 that is glycosylated and secreted from infected cells in an oligomeric form. An adenovirus recombinant, RAd51, expressing high levels of TBEV NS1 has previously been demonstrated to protect mice against a lethal challenge with TBEV. We show here that BALB/c mice infected with TBEV experienced a transient viraemia between days 3 to 5 post-inoculation that was detectable prior to the encephalitic phase of infection. Mice vaccinated with RAd51 were protected against both the viraemic and encephalitic infections associated with the TBEV challenge. Protection was demonstrated to be due to NS1 synthesized from RAd51 in the vaccinated mice. Since TBEV NS1 is expressed on the cell surface, antibody-dependent complement-mediated cytolysis (CMC) of infected cells was considered as a possible mechanism of protection. Vaccination with the recombinant adenovirus proved to be effective in a mouse strain carrying a genetic deletion in the complement receptor C5. CMC is therefore not an essential component of the observed protective immune response.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-75-9-2399
1994-09-01
2021-10-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/75/9/JV0750092399.html?itemId=/content/journal/jgv/10.1099/0022-1317-75-9-2399&mimeType=html&fmt=ahah

References

  1. Barrett A. D. T., Gould E. A. 1986; Antibody-mediated early death in vivo after infection with yellow fever virus. Journal of General Virology 67:2539–2542
    [Google Scholar]
  2. Calisher C. H., Karabatsos N., Dalrymple J. M., Shope R. E., Porterfield J. S., Westaway E. G., Brandt W. E. 1989; Antigenic relationships between flaviviruses as determined by cross�neutralization test with polyclonal antisera. Journal of General Virology 70:37–43
    [Google Scholar]
  3. De Madrid A. T., Porterfield J. S. 1974; The flaviviruses (group B arboviruses): a cross-neutralization study. Journal of General Virology 23:91–96
    [Google Scholar]
  4. Falgout B., Bray M., Schlesinger J. J., Lai C. -J. 1990; Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus non-structural protein NS1 protects against lethal dengue virus encephalitis. Journal of Virology 64:4356–4363
    [Google Scholar]
  5. Gould E. A., Buckley A. 1989; Antibody-dependent enhance�ment of yellow fever virus neurovirulence. Journal of General Virology 70:1605–1608
    [Google Scholar]
  6. Gould E. A., Buckley A., Barrett A. D. T., Cammack N. 1986; Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. Journal of General Virology 67:591–595
    [Google Scholar]
  7. Gould E. A., Buckley A., Groeger B. K., Cane P. A., Doenhoff M. 1987; Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. Journal of General Virology 68:3105–3112
    [Google Scholar]
  8. Halstead S. B. 1982; Immune enhancement of virus infection. Progress in Allergy 31:301–364
    [Google Scholar]
  9. Hawkes R. A. 1964; Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Australian Journal of Biological Sciences 42:465–482
    [Google Scholar]
  10. Hawkes R. A., Lafferty K. J. 1967; The enhancement of virus infectivity by antibody. Virology 33:250–261
    [Google Scholar]
  11. Heinz F. X., Kunz C. 1981; Homogeneity of the structural glycoprotein from European isolates of tick-borne encephalitis virus: comparison with other flaviviruses. Journal of General Virology 57:263–274
    [Google Scholar]
  12. Jacobs S. C., Stephenson J. R., Wilkinson G. W. G. 1992; High level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. Journal of Virology 66:2086–2095
    [Google Scholar]
  13. Kayser M., Klein H., Paasch I., Pilaski J., Blenk H., Heeg K. 1985; Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. Journal of Medical Virology 17:35–45
    [Google Scholar]
  14. Phillpotts R. J., Stephenson J. R., Porterfield J. S. 1985; Antibody-dependent enhancement of tick-borne encephalitis virus infectivity. Journal of General Virology 66:1831–1837
    [Google Scholar]
  15. Precious B., Russell W. C. 1985; Growth, purification and tritration of adenoviruses. In Virology: A Practical Approach pp 193–205 Mahy B. W. J. Edited by Oxford: IRL Press;
    [Google Scholar]
  16. Schlesinger J. J., Brandriss M. W., Walsh E. E. 1985; .Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the non-structural glycoprotein gp48 and by active immunization with Gp48. Journal of Immunology 135:2805–2809
    [Google Scholar]
  17. Schlesinger J. J., Brandriss M. W., Cropp C. B., Monath T. P. 1986; Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. Journal of Virology 60:1153–1155
    [Google Scholar]
  18. Schlesinger J. J., Brandriss M. W., Walsh E. E. 1987; Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. Journal of General Virology 68:853–857
    [Google Scholar]
  19. Schlesinger J. J., Foltzer M., Chapman S. 1993; The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192:132–141
    [Google Scholar]
  20. Stephenson J. R., Lee J. M., Wilton-Smith P. D. 1984; Antigenic variation among members of the tick-borne encephalitis complex. Journal of General Virology 65:81–89
    [Google Scholar]
  21. Wilkinson G. W. G., Akrigg A. 1992; Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Research 20:2233–2239
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-75-9-2399
Loading
/content/journal/jgv/10.1099/0022-1317-75-9-2399
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error